Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spero Therapeutics (SPRO) EBIT (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed EBIT for 10 consecutive years, with -$7.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBIT rose 60.3% year-over-year to -$7.4 million, compared with a TTM value of -$46.3 million through Sep 2025, down 4092.21%, and an annual FY2024 reading of -$73.4 million, down 441.52% over the prior year.
  • EBIT was -$7.4 million for Q3 2025 at Spero Therapeutics, down from -$2.4 million in the prior quarter.
  • Across five years, EBIT topped out at $50.5 million in Q4 2023 and bottomed at -$30.2 million in Q1 2022.
  • Average EBIT over 5 years is -$11.0 million, with a median of -$14.7 million recorded in 2025.
  • The sharpest move saw EBIT surged 178.35% in 2022, then tumbled 1770.52% in 2024.
  • Year by year, EBIT stood at -$27.5 million in 2021, then skyrocketed by 178.35% to $21.5 million in 2022, then soared by 134.52% to $50.5 million in 2023, then tumbled by 142.99% to -$21.7 million in 2024, then skyrocketed by 66.02% to -$7.4 million in 2025.
  • Business Quant data shows EBIT for SPRO at -$7.4 million in Q3 2025, -$2.4 million in Q2 2025, and -$14.7 million in Q1 2025.